Hydrochloric Acid

Hydrochloric Acid

SCHEMBL6764904

C1=C2CCC3=Cc4ccccc4C3[Ti+2]C2c2ccccc21.[Cl-].[Cl-]

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.37
DRD2 P14416 4/20 0.31
DRD4 P21917 4/20 0.31
CYP19A1 P11511 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7783233 0.88 CYP19A1 (0.31) KDM1ACYP19A1CYP11B1CYP11B2
SCHEMBL8155989 0.81 DRD2 (0.30) DRD2DRD4
Hydrochloric Acid SCHEMBL216904 0.72 KDM1A (0.37) KDM1ACYP19A1CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL3645288 0.72 KDM1A (0.37) KDM1ACYP19A1CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL217217 0.72 KDM1A (0.37) KDM1ACYP19A1CYP11B1CYP11B2
SCHEMBL3641346 0.71 KDM1A (0.39) KDM1A
SCHEMBL577658 0.71 KDM1A (0.39) KDM1A
SCHEMBL2046288 0.71 KDM1A (0.39) KDM1A
SCHEMBL5033883 0.69 KDM1A (0.38) KDM1A
SCHEMBL2236198 0.69 KDM1A (0.38) KDM1ADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3074450-B1 MOISTURE CURABLE COMPOUND WITH METAL-ARENE COMPLEXES MOMENTIVE PERFORMANCE MAT INC (US) 2020-11-11 EP disclosed
CN-105793326-B Moisture-curable compositions with metal-arene complexes 莫门蒂夫性能材料股份有限公司 2020-07-21 CN disclosed
US-10174169-B2 Moisture curable compound with metal-arene complexes MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2019-01-08 US disclosed
US-20170260335-A1 MOISTURE CURABLE COMPOUND WITH METAL-ARENE COMPLEXES MOMENTIVE PERFORMANCE MATERIALS INC. 2017-09-14 US disclosed
EP-0996647-B1 PROCESS FOR THE PRODUCTION OF OLEFIN POLYMERS HAVING A DESIRABLE MOLECULAR WEIGHT DISTRIBUTION BOREALIS TECH OY (FI) 2004-09-08 EP disclosed
US-6723676-B2 USE AS CATALYSTS FOR THE (CO) POLYMERIZATION OF OLEFINIC AND/OR DIOLEFINIC MONOMERS. BAYER AKTIENGESELLSCHAFT (DE) 2004-04-20 US disclosed
US-20030027954-A1 1,3-disubstituted indene complexes BAYER AKTIENGESELLSCHAFT (DE) 2003-02-06 US disclosed
EP-0849292-B1 Olefin polymerisation catalysts and processes for producing olefin polymers TOSOH CORP (JP) 2002-08-21 EP disclosed
EP-1136122-A1 TRANSITION METAL CATALYSTS AND PROCESSES FOR PRODUCING $g(a)-OLEFIN AND VINYL COMPOUND POLYMER IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2001-09-26 EP disclosed
US-6110858-A AN OLEFIN POLYMERIZATION CATALYST CONSISTS OF A TRANSITION METAL COMPOUND, A MODIFIED CLAY COMPOUND CONTAINING CLAY MINERAL AND AN AMINE COMPOUND AND AN ORGANOALUMINUM COMPOUND TOSOH CORPORATION (JP) 2000-08-29 US disclosed
EP-0996647-A1 PROCESS FOR THE PRODUCTION OF OLEFIN POLYMERS HAVING A DESIRABLE MOLECULAR WEIGHT DISTRIBUTION BOREALIS A/S (DK) 2000-05-03 EP disclosed
WO-1999003897-A1 PROCESS FOR THE PRODUCTION OF OLEFIN POLYMERS HAVING A DESIRABLE MOLECULAR WEIGHT DISTRIBUTION BOREALIS A/S (DK) 1999-01-28 WO disclosed
EP-0849292-A1 Olefin polymerisation catalysts and processes for producing olefin polymers TOSOH CORPORATION (JP) 1998-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027954-A1 1,3-disubstituted indene complexes ORC3, IDO1, IDH3A KDM1A 2557/4885DRD2 1017/4885DRD4 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.